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Cerebral small vessel disease (CSVD) is a common group of neurological conditions that confer a 
significant burden of morbidity and mortality worldwide. In most cases, CSVD is only recognized 
in its advanced stages once its symptomatic sequelae develop. However, its significance in 
asymptomatic healthy populations remains poorly defined. In population-based studies of 
presumed healthy elderly individuals, CSVD neuroimaging markers including white matter 
hyperintensities, lacunes, cerebral microbleeds, enlarged perivascular spaces, cortical superficial 
siderosis, and cerebral microinfarcts are frequently detected. While the presence of these imaging 
markers may reflect unique mechanisms at play, there are likely shared pathways underlying 
CSVD. Herein, we aim to assess the etiology and significance of these individual biomarkers by 
focusing in asymptomatic populations at an epidemiological level. By primarily examining 
population-based studies, we explore the risk factors that are involved in the formation and 
progression of these biomarkers. Through a critical semi-systematic review, we aim to characterize 
“asymptomatic” CSVD, review screening modalities, and draw associations from observational 
studies in clinical populations. Lastly, we highlight areas of research (including therapeutic 
approaches) in which further investigation is needed to better understand asymptomatic CSVD. 
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Introduction
Several of the recent developments1-5 in stroke care have fo-
cused on the treatment of large vessel occlusions and patholo-
gies. However, there have been few advancements in the man-
agement of cerebral small vessel disease (CSVD) largely be-
cause small vessels are difficult to observe radiographically and 
their underlying pathogenic mechanisms are incompletely un-
derstood.6,7 This is problematic given that CSVD contributes to 
a number of clinically relevant sequelae including hemorrhagic 
stroke, vascular cognitive impairment (VCI), gait disturbances 
including parkinsonism, bladder dysfunction, and epilepsy.7-13 
Furthermore, a large proportion of ischemic stroke and demen-
tia are attributed to CSVD (20% and 45%, respectively).14 One 
of the greatest challenges is that there are limited means to 
assess CSVD prior to the development of its clinical sequelae. 
Moreover, even after identification of CSVD in healthy popula-
tions, management of this disease is not well established. In 
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this review, we aim to summarize basic definitions of CSVD 
and CSVD biomarkers, highlight our current understanding of 
CSVD as it relates to “healthy” populations, and where relevant, 
incorporate evidence from observational studies in different 
clinical populations. We will focus on asymptomatic CSVD, de-
fined as neuroimaging evidence of CSVD prior to the develop-
ment of any overt clinical symptoms. Although we will review 
the major population-based studies in the field, we will cross-
link our findings with those of clinical cohorts to unravel clini-
cal relevance and put data into perspective. The emphasis of 
this paper will be sporadic non-amyloid CSVD (often termed 
“hypertensive arteriopathy”),7 as there are several recent re-
views that discuss monogenetic CSVD and cerebral amyloid 
angiopathy (CAA)-related CSVD.15-18 
Methods
Search strategy and selection criteria
Articles from January 1951 to July 2018 were identified through 
searching the PubMed (National Center for Biotechnology Infor-
mation, National Library of Medicine) database. The following ti-
tle/abstract search terms were employed: “cerebral small vessel 
disease AND population,” “silent lacunar infarcts AND popula-
tion,” “white matter hyperintensities AND population,” “cerebral 
microbleeds AND population,” “perivascular spaces AND popula-
tion,” “cortical superficial siderosis AND population,” and “cere-
bral microinfarcts AND population.” Exclusion terms were not 
used in the search criteria. Searches were limited to full-text ar-
ticles available in English. Additional references were selected by 
reviewing the reference lists of relevant publications. As this re-
view was restricted to asymptomatic disease, most articles dis-
cussing symptomatic stroke or intracerebral hemorrhage (ICH) 
were excluded. Furthermore, we excluded literature pertaining to 
CAA given that our focus was on sporadic, non-amyloid CSVD. 
Data analysis
By using the above search methodology, 642 articles were gen-
erated. Articles were independently screened by two authors 
(A.S.D. and R.W.R.) for appropriateness and relevance to the 
topic. Two hundred and eight articles were ultimately selected 
for incorporation in this review. Using this analysis, we gener-
ated a semi-systematic review.
CSVD definitions
CSVD is a broad term that incorporates both neuroimaging and 
neuropathological findings that pertain to smaller vessels (5 µm 
to 2 mm) in the gray and white matter including arterioles, cap-
illaries, and venules.6,7,14,19 While both concepts have been raised 
in the literature, it should be noted that neuroimaging markers 
reflect CSVD, but do not define the disease in its entirety. CSVD 
is often diagnosed by neuroimaging features seen occasionally 
on computed tomography (CT), but more sensitively detected by 
magnetic resonance imaging (MRI). These MRI markers include 
white matter hyperintensities (WMHs) of presumed vascular ori-
gin, recent small subcortical infarcts and lacunes, cerebral mi-
crobleeds (CMBs), perivascular spaces (PVSs), cortical superficial 
siderosis (cSS), brain atrophy, and cerebral microinfarcts (CMIs) 
(Figure 1).7,14 In 2013, these imaging markers (with the exception 
of CMI) were defined by the STandards for ReportIng Vascular 
changes on nEuroimaging (STRIVE) consortium, which unified 
definitions of CSVD biomarkers based on key neuroimaging char-
acteristics.20 In most cases, not all of these neuroimaging mark-
ers will be present together in a single brain scan. Whether the 
presence or anatomical location of certain imaging markers re-
flects distinct small vessel pathways is not fully understood.
While the true burden of CSVD is not known, estimates sug-
gest that at least one-third of healthy-populations have lacu-
nes (the majority of which are due to CSVD), although the ac-
tual prevalence of CSVD is likely much higher.21,22 While these, 
often called “silent strokes,” are visible on CT or MRI, they por-
Figure 1. Imaging features of cerebral small vessel disease biomarkers on 
magnetic resonance imaging. (A) T2 fluid attenuated inversion recovery (FLAIR) 
sequence depicting white matter hyperintensities (red arrowhead) which are 
seen as hyperintense regions in the white matter. (B) Lacune (red arrowhead) 
on FLAIR sequence characterized by a central hypointensity with a surround-
ing rim of hyperintensity. (C) Recent subcortical infarct (red arrowhead) on 
diffusion-weighted imaging sequence between 3 to 15 mm in diameter. (D) 
Susceptibility-weighted imaging (SWI) sequence showing cerebral microbleeds 
(red arrowhead) which are round/oval shaped signal voids ≤10 mm and have 
associated blooming artifact. (E) Perivascular spaces (red arrowhead) on T2 
which are linear cavitations that do not have a surrounding rim of hyperinten-
sity and are <3 mm in diameter. (F) Cortical superficial siderosis (red arrow-
head) visualized on SWI and characterized by a curvilinear hypointensity that 
follows the gyral surface. (G) Cerebral microinfarct (<5 mm in diameter) is hy-
perintense on T2 FLAIR (see inset, red arrowhead) and (H) hypointense on T1 
(see inset, red arrowhead). Images (G) and (H) were graciously provided by Su-
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tend no clinical syndrome because of their small size and non-
eloquent location (sparing motor cortices, cranial nerves, or 
language centers). However, in patients without CSVD visible 
on 1.5T MRI, infarcts may still be present, but visible only on 
ultra-high resolution (7T) MRI images or by pathologic exami-
nation. The burden of these CMI can be formidable, with esti-
mates suggesting hundreds to thousands of infarcts in a single 
brain.23-25 This fact underscores the difficulty of diagnosing and 
ascertaining the extent of CSVD, such that the mere presence 
of one biomarker such as WMH can reflect a much larger pro-
cess involving several pathological disruptions to the cerebral 
microvasculature.26 
CSVD is a dynamic process in which lesions including WMH, 
CMB, and lacunes can progress or regress (even after account-
ing for differences in MRI technique).27,28 The implications of 
this on CSVD is not well understood but may be a balance be-
tween small vessel arteriopathy and neural repair processes. 
Hypertension and other vascular risk factors are believed to be 
the primary culprits of this entity as we will see from several 
epidemiological studies. Herein, we aim to review the epidemi-
ological studies that pertain to each of the major neuroimag-
ing markers. We limit discussion of brain atrophy, given that it 
can reflect a host of underlying mechanisms beyond CSVD.
White matter hyperintensities of 
presumed vascular origin
WMH of presumed vascular origin, often termed leukoaraiosis 
in early reports,29-31 are of variable size, but appear hyperintense 
on T2-weighted (T2) and fluid attenuated inversion recovery 
(FLAIR) MRI sequences and hypointense/isointense on T1-
weighted sequences.20 They are more difficult to detect on CT, 
but may be seen as hypodensities (or hypoattenuated areas). 
Typically, they spare the subcortical U-fibers, and presumably 
are due to chronic hypoperfusion with increased blood-brain 
barrier permeability,31-33 although pathological reports have 
been infrequent and discordant.34 Mechanistic insight provided 
by advanced neuroimaging methods suggests that there are 
likely early alterations in interstitial fluid mobility that eventu-
ally lead to demyelination and axonal damage.34 Because WMH 
are highly prevalent in “healthy” populations (Table 1),35-44 it re-
mains unclear whether WMH are always pathologic. However, 
punctate WMH are probably due to a variety of causes and 
have relatively low risk for further progression. On the other 
hand, confluent WMH are likely to progress in a more aggres-
sive fashion.45 While not fully clear, subcortical WMH and peri-
ventricular WMH may represent the same spectrum of disease 
leading to devastating clinical outcomes.34,46 Because of limita-
tions in neuroimaging techniques and MRI processing methods, 
differentiating WMH from other lesions or artifacts (such as 
corticospinal tracts or blood flow) can be difficult.34 
Several population-based studies have explored the risk fac-
tors associated with development of CSVD. The major studies 
include the Cardiovascular Health Study (CHS), Austrian Stroke 
Prevention Study (ASPS), Rotterdam Study (RS), and Athero-
sclerosis Risk in Communities Study (ARIC). While these studies 
have yielded several conflicting results, there are some patterns 
that have emerged. In the CHS,35,36,47-53 a longitudinal study of 
elderly (≥65 years) community-dwelling adults, approximately 
three-fourths of the study population exhibited periventricular 
Table 1. Major population-based studies of WMH in healthy subjects








WMH progression risk factors
Cardiovascular Health 
Study35,36
1989 3,301 74 96 Age, silent infarct, SBP, 
lower FEV1, low income
28 (5) Age, DBP, decreased LDL (low grade); 
diuretics use, statin use (high grade); 
cigarette smoking, baseline infarct 
(both)
Austrian Stroke Prevention 
Study40,41
2005 273 60 65 NR 17.9 (3) Baseline WMHV, DBP
Rotterdam Scan Study37,38 1990 1,077 72 95 Age, female gender 39 (3.4) Baseline WMHV, female sex, age, BP, 
smoking
Atherosclerosis Risk in 
Communities Study39,42
1987 1,920 62 86 Age, smoking, alcohol use, 
education, SBP, DBP, Af-
rican American race
23 (9) SBP, smoking
Framingham Offspring Co-
hort Study43,44
1948 1,814 53 NR Smoking, hypertension NR (10) Smoking, BP
For each population-based study, the percentage of patients with WMHs is shown. The percentage of individuals with WMH progression is shown as well as 
the duration of study in parenthesis. Risk factors for WMH formation as well as progression are listed. 
WMH, white matter hyperintensity; SBP, systolic blood pressure; FEV1, forced expiratory volume in 1 second; DBP, diastolic blood pressure; LDL, low-density li-
poprotein; NR, not reported; WMHV, white matter hyperintensity volume; BP, blood pressure.
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rather than subcortical WMH and about one-fifth of popula-
tion had equal distributions in both regions. Higher WMH bur-
den was associated with older age, asymptomatic stroke on 
MRI, higher systolic blood pressure (BP), smoking, and female 
gender, with age showing the strongest correlation.35 By con-
trast, the majority of WMH in the RS, a population based-co-
hort study that recruited nondemented individuals aged 60 to 
90 years,37,54-57 were found in subcortical areas and to greater 
extent in frontal and parietal regions.37,38 As shown in a sub-
study of the RS, arterial stiffness (as measured by the aortic 
pulse wave velocity) was associated with larger WMH volumes 
independent of cardiovascular risk factors.58 Similar to CHS, 
WMH were also associated with increasing age. Regardless of 
age or anatomic location, women had a higher burden of white 
matter lesions (both in periventricular and subcortical areas) 
consistent with findings from the PROspective Study of Pravas-
tatin in the Elderly at Risk (PROSPER) study59,60 as well as CHS. 
This may be due to decreased estrogen after menopause allow-
ing the brain to be more prone to hypoxia.37 Interestingly, in a 
longitudinal substudy of PROSPER,59 deep WMH progression 
among women was twice that of men, whereas the increase in 
periventricular WMH was similar.60 In the ARIC study, a pro-
spective study that recruited middle-aged men and women,61 
hypertension was associated with WMH.39,62 For unclear rea-
sons, blacks had a lower prevalence of WMH, but a higher 
prevalence of severe WMH.63 In a follow-up study, blacks, who 
had a higher incidence of baseline hypertension, experienced 
more WMH progression than Caucasians.64 Unlike many of the 
other population-based studies (in which blacks were less rep-
resented), this finding suggests that hypertension may influ-
ence CSVD progression. However, it is uncertain whether black 
race is independently associated with WMH burden or whether 
hypertension contributes indirectly. In addition to blacks, 
Asians have a high burden of CSVD,65,66 although the location 
of their WMH is similar to that of Europeans, but more strongly 
associated with age.67 Similar to blacks, hypertension is also 
strongly associated with WMH burden in Asian populations.68
In early longitudinal studies, baseline CSVD (lacunes and 
WMH) seems to have the strongest association with WMH 
progression, although there has been conflicting information 
regarding whether WMH progression occurs in periventricular 
or subcortical (deep) areas.69-73 In follow-up studies examining 
the progression of WMH in the CHS, the risk of clinical stroke 
was increased among patients with high baseline WMH bur-
dens and asymptomatic strokes.36,52,74 Interestingly, with the 
exception of cigarette smoking and presence of an infarct on 
baseline MRI, the relationship between risk factors and WMH 
progression was dependent on low versus high WMH burden 
at initial scan (Table 1).36 Baseline WMH burden was also found 
to be important in the ASPS, a single-center population-based 
study that enrolled around 2,000 individuals in Graz, Austria, 
ages 50 to 75.40,75 In a 3-year period, subcortical WMH pro-
gression occurred in deep and subcortical areas, and was asso-
ciated with diastolic BP as well as baseline WMH burden.40 
However, in a 6-year follow-up study, only baseline WMH 
grade was ultimately associated with WMH progression.41,76 
Similar to the ASPS, the RS showed that WMH progression oc-
curs in subcortical areas compared to periventricular areas,38 a 
finding which was also replicated in the Leukoaraiosis And 
DISability study (LADIS).72 Interestingly, one Japanese study of 
neurologically healthy adults demonstrated that subcortical 
WMH were more associated with increased future risk of 
stroke than periventricular WMH, although periventricular 
WMH were associated with an increased risk of death.46 In the 
RS, WMH progression was associated with a broad range of 
previously-identified risk factors38,77 and in young patients and 
in patients without severe WMH at baseline, hypertension was 
strongly associated with lesion progression. Interestingly, a 
small percentage of subjects demonstrated WMH regression in 
subcortical areas (and to a much lesser extent periventricular 
areas), highlighting the dynamic nature of CSVD.27 
In the Framingham Offspring study, WMH were associated 
with an increased risk of symptomatic stroke, dementia, am-
nestic cognitive impairment, and death.78-82 Similar studies 
have shown that WMH can modulate the progression from 
normal to mild cognitive impairment,83 with periventricular 
WMH playing a more critical role than deep/subcortical 
WMH.84,85 In the RS, apolipoprotein (APOE) ε4 carriers, which 
have increased rates of Alzheimer’s disease,86 had higher WMH 
burdens, especially if carriers had comorbid hypertension. This 
has been corroborated by other studies relating APOE to WMH 
burden.87-89 In the RS, 4.2% of subjects developed dementia, 
which was associated with a higher burden of periventricular 
WMH compared to subcortical WMH.90 
Recent small subcortical infarcts and 
lacunes
Because of advancements in neuroimaging that have led to 
improved detection of asymptomatic infarcts, the STRIVE con-
sortium separated lacunar stroke into recent small subcortical 
infarct and lacune of presumed vascular origin.20 Lacunes likely 
represent the chronic end-product of small subcortical infarcts. 
Recent small subcortical infarcts are sometimes accompanied 
by clinical lacunar syndromes, as initially described by Fish-
er,91,92 or they can be found incidentally by lesions with re-
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stricted diffusion on diffusion-weighted imaging (DWI) without 
an accompanying clinical stroke syndrome.93,94 Small subcorti-
cal infarcts are dynamic, and over-time, can disappear, cavitate 
(forming lacunes), or form WMH.27,95,96 On imaging, small sub-
cortical infarcts follow the territory of a perforating arteriole, 
are <20 mm in maximal diameter, and exclude striatocapsular 
infarcts and anterior choroidal infarcts (which have a different 
underlying etiology). They are relatively easy to detect on MRI 
because they appear hyperintense on DWI and hypointense on 
apparent diffusion coefficient images. Pathologically, they are 
presumably due to occlusion of small perforating arterioles 
through a variety of mechanisms including microatheromatous 
disease or cardioembolism.
Lacunes of presumed vascular origin are appropriately 
named given the fluid-filled cavity that is often found after a 
lacunar stroke. By consensus definitions, lacunes are a round or 
ovoid, subcortical, fluid-filled cavity between 3 and 15 mm in 
diameter. They follow the signal intensity of cerebrospinal fluid 
on all sequences and on FLAIR images, and they have a central 
hypointensity with a surrounding rim of hyperintensity (in con-
trast to PVS).20 Incidental small subcortical infarcts are not 
commonly observed at high-frequencies in studies of asymp-
tomatic populations, and so therefore our analysis will be lim-
ited to lacunes. Given that previous analysis of lacunes have 
been reviewed systematically,10,97 we will highlight only the 
major population-based studies. 
In healthy populations, the frequency of lacunes ranges from 
8% to 31% (owing to differences in the ages of the study pop-
ulations and variability in spatial resolution of imaging stud-
ies).21,41,51,52,56,68,98 Although the associated risk factors have var-
ied between studies, hypertension, age, and (to a lesser degree) 
smoking, seem to be the most replicated.21,56,68,98,99 Conflicting 
associations between gender and infarct presence have been 
observed: in the CHS and Shunyi Study, male gender was found 
to be associated,21,68 and in the RS, female gender was found to 
be associated.56 Other less robust risk factors that have been 
shown to be associated with silent lacunes include serum cre-
atinine,21 diabetes,21,68,99 cholesterol,99 homocysteine levels,99 
and black race.98 Interestingly, carotid atherosclerosis was 
found to be associated with silent lacunes, suggesting that 
small subcortical infarcts can occur through artery-artery em-
bolism or flow limiting effects.21,98,99 
In these studies, lacunes were typically found in the lenti-
form nucleus and thalamus21 whereas a large portion of symp-
tomatic infarcts were found in the cerebral cortex, thereby in-
voking other etiologies such as internal carotid artery athero-
sclerosis or atrial fibrillation.52 Although many of these individ-
uals did not experience any clinical symptoms of stroke, they 
were more likely to perform poorly on neuropsychological test-
ing, highlighting the “covert” nature of CSVD.53 In longitudinal 
studies, the progression of lacunes occurs in 3.5%53 to 4.1%99 
of subjects annually. Baseline cerebrovascular disease (WMH 
and lacunes) seems to be the most prominent risk factor for 
development of additional lacunar infarcts, which are predomi-
nantly located in subcortical regions53 or in the deep basal 
ganglia.56 The association between baseline WMH and infarct 
development suggests that there may be a common pathway 
underlying these two markers. Similarly, symptomatic strokes 
are likely to represent a lesion in the same spectrum as asymp-
tomatic strokes. Individuals with these silent brain infarcts are 
twice as likely to develop symptomatic stroke, which share 
many of the same risk factors as silent infarcts.52 Of the indi-
viduals that experienced a symptomatic stroke during follow-
up studies, the majority were more likely to have a silent lacu-
nar stroke or a higher WMH burden on their initial MRI.100 
Cerebral microbleeds
CMBs are areas (≤10 mm) of round/oval shaped signal voids 
with blooming effect on MRI, best seen on T2*-weighted gra-
dient-recalled echo (GRE) or susceptibility-weighted imaging.101 
They are located in the cortico-subcortical junction and deep 
gray or white matter throughout the brain (including brain-
stem and cerebellum).20,102 Histopathologically, in microangiop-
athies that affect small penetrating vessels (such as non-CAA 
CSVD/”hypertensive vasculopathy” or CAA), there is often ex-
travasation of blood products into perivascular tissues leading 
to activation of macrophages; these foci of hemosiderin-laden 
macrophages are representative of microbleeds.103 Clinically, 
they are associated with ICH and stroke (especially in CAA).104 
However, the clinical significance of CMB in healthy popula-
tions is poorly understood.
CMB are a common finding in “healthy” populations. The 
prevalence of CMB ranges from 3.1%105 to 15.3%106 owing to 
differences in the sensitivity of MRI sequences used (Table 2). In 
subjects with CMB, the majority have <3 lesions located in cor-
tico-subcortical areas.107-112 However, in non-European popula-
tions, CMB are found more predominantly in deep areas, which 
may be related to increased rates of hypertension although the 
prevalence of CMB is relatively the same.68,111,113,114 While several 
risk factors are associated with CMB presence, the two most 
consistently associated are age and hypertension.68,105-107,110,111,115 
For example, in the Framingham Study Original Cohort and Off-
spring Cohort,108,109 the prevalence of CMB was 12.6% in pa-
tients 75 years of age or older compared to 2.2% in patients 
younger than 75. With improved detection sensitivity using 3D-
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GRE in the RS, CMB prevalence was 18% in individuals aged 60 
to 69 years and 38% in patients older than 80.116 In addition, 
three studies68,110,115 have found higher rates of CMB in males, 
although other studies have not reported any gender differences 
in CMB prevalence.107 As seen in other CSVD biomarkers, smok-
ing was also identified as a risk factor in two studies105,106 while 
diabetes and hypercholesterolemia may be less important (Table 
2).68,113 Given the overlap of risk factors in CMB, WMH, and la-
cunes, there are likely shared underlying mechanisms that give 
rise to these biomarkers. Indeed, several studies have demon-
strated an increased prevalence of CMB if concomitant WMH 
and lacunes were present.106,107,111,113
As with other biomarkers, the location of CMB may be re-
flective of distinct underlying etiologies. In the ASPS, all indi-
viduals with deep CMB had hypertension, whereas only 50% of 
individuals with cortico-subcortical CMB had hypertension.107 
In the Framingham Study,108,109 almost three-fourths of the 
study population had CMB in the cortex, whereas 23% were 
located in deep regions. Unlike the aforementioned studies, hy-
pertension was not associated with CMB, perhaps explained by 
the fact that this study included fewer subjects with deep CMB 
(of which hypertension is more related). In the Age Gene/Envi-
ronment Susceptibility (AGES)-Reykjavik study,117 larger micro-
bleeds were associated with hypertension, and unlike the ASPS, 
CMB presence was associated with ApoE ε4 homozygosity.110 
Similar to the Framingham Study, 70% of subjects had CMB 
located in cortex, whereas 11% had deep CMBs, and 19% had 
infratentorial CMB. Based on these findings, CAA seemed prev-
alent in their population, and given the association with ApoE, 
CAA was likely the etiologic culprit. From the RS,116 ApoE ε4 
carriers had more lobar CMB compared to noncarriers, whereas 
patients with cardiovascular risk factors (hypertension, smok-
ing), silent lacunar infarcts, and WMH had more deep or in-
fratentorial CMB. These findings correlate with observed find-
ings in ICH,118 and arterial stiffness findings in stroke patients.119 
Interestingly, in a follow-up analysis of the RS,120 it was shown 
that CMB were more prevalent (odds ratio [OR], 1.71) in pa-
tients taking antithrombotic medications (platelet aggregation 
inhibitors), but not in patients on anticoagulant medications. 
However, it is worth noting that CMB prevalence may be con-
founded by some indications for antiplatelet treatment, such 
as stroke.121 Patients with strictly lobar CMB were found in a 
higher proportion among aspirin users (OR, 2.70) compared to 
carbasalate calcium users (a combination formula of calcium 
acetylsalicylate and urea; OR, 1.16), suggesting that aspirin 
worsens CMB burden in patients with CAA. 
Even in clinically healthy persons, the presence of CMB cor-
relates with numerous future risks. In the RS, the presence of 
CMB almost doubled the risk of ischemic stroke in a 5-year pe-
riod, with greater CMB count associated with higher stroke 
risk.118 In the PROSPER trial, subjects with greater than 1 CMB 
had a six-fold increase in stroke-related death than those 
without CMB.122 Nonlobar CMB were associated with an in-
creased risk of cardiovascular death whereas lobar CMB was 
associated with an elevated risk of stroke-related death.123 
CMB have also been associated with gait disturbances in non-
demented persons.112,124 Furthermore, subjects with ≥2 CMB 
performed poorly on tests of processing speed and executive 
function, especially those with multiple, deep or infratentorial 
CMB.125 The presence of these deep CMB doubled the risk of 
Table 2. Prevalence and risk factors of CMBs in healthy populations
Population-based study Year Study size Mean age (yr) MRI field strength (T) Prevalence (%) Risk factors
Austrian Stroke Prevention 
Study107
1999 280 60 1.5 6.4 Age, HTN, SSI, WMH
Tsushima et al.105 2002 450 53 1.0 3.1 HTN and smoking
Framingham Study115 2004 472 64 1.0 4.7 Age, male gender
AGES-Reykjavik110 2008 1,962 76 1.5 11.1 Age, male gender, APOE ε4 status
Rotterdam Scan Study106 2010 3,979 60 1.5 15.3 SBP, HTN, smoking, SSI, WMH
RUN-DMC112 2011 485 66 1.5 10.7 NR
Atahualpa Project111 2015 258 70 1.5 11.0 WMH, SSI, brain atrophy
Mitaki et al.113 2017 4,024 62 1.5 4.1 WMH (lobar CMB), low TC and HDL-C (deep 
CMB)
Shunyi Study68 2018 1,211 56 3.0 10.6 Age, hypertension (deep CMB), male gender, 
low LDL-C (deep CMB)
Note that all studies used gradient-echo T2*weighted sequences. 
CMB, cerebral microbleed; MRI, magnetic resonance imaging; T, Tesla; HTN, hypertension; SSI, small subcortical infarct; WMH, white matter hyperintensities; 
APOE ε4, apolipoprotein ε4; SBP, systolic blood pressure; NR, not reported; TC, total cholesterol; HDL-C, high-density lipoprotein-C; LDL-C, low-density lipo-
protein-C. 
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vascular dementia (VaD). Subjects with both CMB and con-
comitant retinopathy were most likely to exhibit slow process-
ing speeds, poor executive function, and VaD.125 Other studies 
have shown that subjects with numerous (≥5) lobar CMB had 
more robust associations with cognitive dysfunction than did 
subjects with deep CMB.106,126 However, in the Framingham 
Heart Study, strictly lobar CMB were not associated with an 
increased risk of dementia.127 Collectively, these studies suggest 
that deep CMB may contribute to cognitive decline through 
mechanisms distinct from lobar CMB-associated cognitive dys-
function.126 The former like reflects sporadic, non-amyloid 
CSVD whereas the latter reflects CAA.
Enlarged perivascular spaces
PVSs, sometimes referred to as Virchow-Robins spaces, are lin-
ear (but can be ovoid or round) projections that follow the path 
of blood vessels. Their significance is unclear, although they may 
be involved in the drainage of interstitial fluid and may be im-
plicated in neurological diseases.128 Normally, they are not well 
visualized by conventional MRI; however, as these spaces dilate 
(with age or other pathological conditions), they may be seen as 
fluid-filled spaces in both the gray and white matter.20 They are 
usually <3 mm in maximal diameter, a cutoff that has often 
been used to distinguish these from lacunes, which also contain 
a hyperintense T2 rim surrounding the cavitation. 
Similar to other biomarkers, the spatial distribution of PVS 
may reflect distinct mechanisms such that deep PVS are likely 
caused by hypertensive-CSVD whereas white matter PVS may be 
more driven by CAA. Such anatomical distinctions have also 
been observed in PVS found after ICH.129 In patients presenting 
to a memory clinic, white matter PVS were associated with lobar 
CMB whereas basal ganglia PVS were associated with older age, 
hypertension, and higher WMH volumes.130 Similarly, in a healthy 
Japanese cohort, basal ganglia PVS were associated with in-
fratentorial CMB, and centrum semiovale PVS were associated 
with strictly lobar CMB.131 Furthermore, basal ganglia PVS were 
associated with hypertension, lacunes, and severe WMH sug-
gesting that these CSVD markers share common substrates. In 
the Three-City (3C)-Dijon Magnetic Resonance Imaging Study, in 
addition to the basal ganglia and white matter, PVS were also 
observed in the hippocampus and hypothalamus.132 In this study, 
PVS were found in all subjects, with approximately one-third be-
ing large (>3 mm). Men appeared to have more basal ganglia 
PVS than woman, although this has not been replicated in other 
studies.133 The severity of both basal ganglia and white matter 
PVS correlated with increasing age.134 With increasing WMH 
volumes and lacunes, the odds of having more severe PVS in the 
basal ganglia was higher than in white matter. 
While several of these studies employ 3 mm as a size cutoff 
to distinguish PVS from lacunes, in imaging-pathological cor-
relation studies, an absolute cutoff size has not been estab-
lished.135 PVS above this size cutoff (termed large PVS) may ac-
tually be common and were found in approximately one-sixth 
of the subjects in the AGES-Reykjavik Study.117,136 The majority 
of these large PVS were located in the basal ganglia and only a 
small fraction of subjects had exclusively white matter PVS. 
After controlling for age and sex, the presence of these deep 
large PVS was associated with silent subcortical infarcts and 
WMH progression. CMB were associated with both deep and 
white matter large PVS. The concurrent presence of PVS and 
other markers of CSVD suggests that there are common under-
lying mechanisms at play.
Although their significance in either healthy or diseased 
populations is not well understood, the presence of PVS may 
confer an increased risk of cognitive decline. In one small study, 
higher numbers of basal ganglia and centrum semiovale PVS 
were associated with poor performance on neuropsychological 
testing.137 Independent of other cerebrovascular risk factors, 
large PVS (>3 mm) were associated with poor processing 
speeds as well as a four-fold increase in VaD risk, but not Al-
zheimer’s dementia (AD) or all-cause dementia risk.136 This is 
consistent with previous studies that observed PVS in higher 
frequencies in patients with VaD compared to AD.138,139 Fur-
thermore, in another population-based study of elderly non-
demented subjects,140 patients with the highest degree of both 
white matter and basal ganglia PVS were most likely to devel-
op dementia over a 4-year period.
Cortical superficial siderosis
cSS are chronic hemorrhagic products that lie under the pia 
mater or in the subarachnoid space and are due to a variety of 
causes including small vascular malformations or CAA.20 They 
are best visualized on paramagnetic MRI sequences given their 
hemosiderin composition, and appear as a linear hypointensity 
over the cortex. 
In the RS, cSS were found in 0.7% of individuals, all of which 
had lobar CMB.141 In these individuals, cSS was located near re-
gions of lobar CMB (frontal and occipital areas). In the most re-
cent Rotterdam data, the prevalence of cSS was 0.4% 
(n=3,401).142 These 15 individuals had concurrent CMB, the ma-
jority (80%) of which were located in lobar regions. In the 1,425 
individuals who received a second MRI at 3 years, two subjects 
developed new cSS, one of which also developed a new lobar 
CMB. Of the seven that had baseline cSS, four showed progres-
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sion of cSS on a follow-up scan. These individuals had several 
lobar CMB on baseline scans ranging from 7 to 130 CMB. 
In another population-based study (n=1,412)143 of individu-
als aged 50 to 89 (of which a portion had dementia or mild 
cognitive impairment144), using data from the Mayo Clinic 
Study of Aging, 13 subjects (0.9%) were found to have cSS. 
Unlike the RS, only about one-fifth of these patients had con-
current CMB, a finding which is consistent with other re-
ports.145 While the presence of the ApoE ε4 allele did not influ-
ence cSS burden, subjects with cSS were more likely to have 
the presence of the APOE ε2 allele, which is associated with 
CAA.146 In a subset of patients who underwent Pittsburgh com-
pound B (PiB) positron emission tomographic scans, those with 
cSS were more likely to be PiB positive (suggestive of high 
β-amyloid burden). Two patients with disseminated cSS had 
follow-up scans which demonstrated progression of both cSS 
and CMB. Although small numbers of subjects had both PiB 
and APOE data, these results suggest that cSS is intimately as-
sociated with CAA. Collectively, these findings suggest that cSS 
may be a marker of CAA-related CSVD rather than hyperten-
sive arteriopathy. cSS is likely a rare finding in healthy popula-
tions but is probably exclusively related to coincident CAA pa-
thology when it is found.
Cerebral microinfarcts
CMI are microscopic, presumed ischemic infarcts, mostly iden-
tified on pathological analysis, but can be seen on 7T MRI 
studies, and occasionally on 3T studies.147-150 Given their ability 
to escape detection using standard neuroimaging protocols 
(1.5T MRI), CMI have not been evaluated extensively in healthy 
individuals. Because their small size (average of 0.2 to 1 mm in 
diameter) is below the spatial resolution (1 mm3) for most con-
ventional MRI field strengths, higher strength MRI machines 
are needed to visualized them.147,151-153 While most of the avail-
able data on CMI has come through post-mortem analysis by 
7T MRI, recently, several groups have reported the ability to 
detect these lesions on 3T MRI in vivo.149,150,154-156 However, the 
sensitivity of detection of 3T is limited compared to 7T,149 and 
can only detect “large” CMI (1 to 3 mm; whereas 7T can detect 
CMI <1 mm).152 As in vivo detection of CMI is relatively recent, 
it has not been incorporated into STRIVE definitions, and there 
have been no consensus definitions established. In some stud-
ies,149,150 CMI have been defined on 3T MRI as hypointense on 
T1-weighted images, hyperintense or isointense on FLAIR and 
T2-weighted images, distinct from PVS, <5 mm in maximum 
diameter, and perpendicular to the cortical surface. 
In patients presenting to a memory clinic in Singapore, the 
prevalence of CMI determined by 3T MRI was 32%.149 The pres-
ence of CMI was associated with hyperlipidemia, history of 
stroke, and cardiovascular disease (even after controlling for 
macroinfarcts). Furthermore, the presence of cortical CMI was 
associated with executive dysfunction as well as lower scores 
on neurocognitive testing with relative sparing of areas involved 
in subcortical disease (attention and visuomotor speed). Not 
surprisingly, patients with cortical CMI were more likely to be 
diagnosed with VaD than those without CMI, although previous 
reports have indicated that the prevalence of individuals with 
CMI was relatively the same between AD patients and non-de-
mented controls.153,157 CMI were associated with both deep and 
lobar CMB, increased WMH burden, and small brain volumes. 
Even after adjusting for WMH, CMB, or macroinfarcts, CMI 
were independently associated with VCI.149 Furthermore, CMI 
were associated with cortical and subcortical macroinfarcts 
(and were not always restricted to the hemisphere of the in-
farct). CMI were also associated with intracranial stenosis of the 
vessel supplying the affected territory. These findings have been 
reproduced in stroke patients, in which it was determined that 
internal carotid artery stenosis was an independent risk factor 
for the development of CMI, and CMI development was associ-
ated with higher stroke recurrence rates.158 Overall, this study of 
memory clinic patients suggests that CMI are a common finding 
in elderly patients with cognitive dysfunction and is in accor-
dance with other population-based neuropathological stud-
ies.159 This study also reported hyperlipidemia as a risk factor for 
CMI whereas previous population-based autopsy studies identi-
fied hypertension as the causative agent.160,161 Interestingly, in 
another analysis using this Singapore cohort,162 29% of subjects 
exhibited CMI on 3T MRI. These patients had an increased fre-
quency of hypertension, hyperlipidemia, cardiac disease, and 
were found to have higher levels of subclinical cardiac biomark-
ers including N-terminal pro-brain natriuretic peptide (nT-proB-
NP) and high-sensitivity cardiac troponin T (hs-cTnT) (after ad-
justing for age, sex, cardiac disease, and other cerebrovascular 
risk factors). In addition, there was an association between atri-
al fibrillation, ischemic heart disease, and congestive heart fail-
ure with cortical CMI. Indeed, in one neuropathological study, it 
was suggested that CMI may be caused by microemboli.163 The 
constellations of these associations including hyperlipidemia, 
intracranial atherosclerosis, and cardiac disease suggests that 
CMI have a heterogenous etiology that arises from shared path-
ways of CSVD, cardioembolism, and large vessel stenosis. 
In another large, population-based study that recruited par-
ticipants from the multiethnic Epidemiology of Dementia in 
Singapore Study (EDIS; n=1,598), 6.3% exhibited at least one 
CMI.164,165 The majority of these were located in the parietal 
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lobes (42%), and to a lesser extent, frontal (21%), occipital 
(12%), and temporal lobes consistent with one earlier small 
study using 7T MRI.157 The presence of other markers of CSVD 
(including lacunar infarcts, WMH, and CMB) as well as macro-
infarcts and intracranial stenosis was greater in patients with 
CMI. Risk factors associated with CMI were increasing age, 
Malay ethnicity, hypertension, diabetes, and history of stroke. 
Although not consistent with previous reports,166,167 the associ-
ation of CMI with diabetes suggests that CMI may also be 
caused by microatheromatous disease at penetrating capillar-
ies. While it was not significant in this study, cigarette smoking 
has been associated with the presence of CMI in other stud-
ies.168 In addition to cerebrovascular risk factors, subjects with 
CMI were more likely to have moderate cognitive impairment 
and dementia.165 Furthermore, the presence of CMI was associ-
ated with poor performance on neuropsychological testing 
even after controlling for lacunar infarcts. Collectively, CMI are 
independently associated with neurocognitive impairment as 
has been observed in neuropathological studies.169
Very few studies have examined whether the anatomical loca-
tion of CMI suggests different risk factors or underlying patholo-
gies. In one recent large population-based neuropathological 
study of elderly community dwelling individuals (n=1,066),170-172 
CMI were found in one-third of subjects. The odds of having one 
or more CMI were increased in patients with atherosclerosis, ar-
teriolosclerosis, and CAA. However, in a subgroup analysis, only 
atherosclerosis and arteriolosclerosis were associated with sub-
cortical CMI, whereas CAA was associated with cortical CMI. 
Similar to other biomarkers, cortical CMI may be associated with 
CAA pathology whereas subcortical CMI may be due to other 
mechanisms such as hypertension.
Screening for CSVD
The major clinical features and associated risk factors for CSVD 
biomarkers are summarized below (Table 3). Currently, screen-
ing of asymptomatic individuals for CSVD is not recommend-
ed.173 The major reasons MRIs are not performed in healthy 
populations is cost and lack of intervenable measures if as-
ymptomatic CSVD is identified. However, more cost-effective 
methods of screening for CSVD may be able to select at-risk 
patients, especially those in high-risk populations, such as 
women or African Americans. These initial studies, if abnormal, 
can prompt further testing including MRI. 
In patients that have received a brain MRI, a total SVD score 
can be calculated to assess the total burden of CSVD.174 This 
visually rated score (ranging from 0 to 4) incorporates WMH, 
lacunes, CMB, and PVS, and reflects the amount of brain injury 
attributable to CSVD.175 Not surprisingly, hypertension, age, 
male gender, and smoking are associated with higher SVD 
scores, highlighting the concept of shared underlying patho-
genic mechanisms. Although it has not been widely adopted in 
clinical practice, this score can assist in stratifying patients at 
risk for ischemic stroke176 or cognitive impairment. Further-
more, it can serve as a surrogate combined marker for CSVD in 
clinical trials focused on secondary prevention.174
In cross-sectional population-based studies, numerous bio-
markers such as fibrinogen, C-reactive protein (CRP), interleu-
kin-6, neurofilament light chain, homocysteine, and D-dimer 
have been associated with the presence of CSVD markers such 
as WMH, lacunes, and PVS.177-179 In two longitudinal population-
based studies, only intercellular adhesion molecule 1 (ICAM-1) 
and CRP have been found to be associated with WMH progres-
Table 3. Summary of biomarkers
Neuroimaging markers Pathological correlate MRI appearance Risk factors Associated CSVD subtype Sequelae
WMH Chronically hypoperfused 
brain parenchyma
Hyperintense on T2 and FLAIR, hypoin-
tense on T1 (variable size)
Age, smoking, 
hypertension
HTN-CSVD, CAA IS, ICH, VaD
Lacunes Chronic fluid-filled end-
product of small subcorti-
cal infarcts
Central hypointensity with surrounding 




HTN-CSVD, CAA IS, ICH, VaD
CMB Foci of hemosiderin-laden 
macrophages
Round/oval shaped signal void (≤10 mm) 
with blooming artifact on T2*, GRE, SWI
Age, smoking, 
hypertension
HTN-CSVD, CAA IS, ICH, VaD
PVS Interstitial fluid-filled spaces 
surrounding blood vessels
Linear cavitation without hyperintense T2 
rim on FLAIR (<3 mm)
Hypertension HTN-CSVD, CAA VaD
cSS Chronic hemorrhagic prod-
ucts underlying pia mater
Curvilinear hypointensity that follows gy-
ral surface on T2*, GRE, SWI
Unknown CAA ICH
CMI Microscopic ischemic in-
farcts
Hypointense on T1, hyperintense on T2/
FLAIR (<5 mm)
Heterogenous HTN-CSVD, CAA VaD
MRI, magnetic resonance imaging; CSVD, cerebral small vessel disease; WMH, white matter hyperintensity; FLAIR, fluid attenuated inversion recovery; HTN, 
hypertensive; CAA, cerebral amyloid angiopathy; IS, ischemic stroke; ICH, intracerebral hemorrhage; VaD, vascular dementia; CMB, cerebral microbleed; GRE, 
gradient echo; SWI, susceptibility-weighted imaging; PVS, perivascular spaces; cSS, cortical superficial siderosis; CMI, cerebral microinfarcts. 
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sion.180,181 However, given that there have been conflicting results 
in these studies,182-185 the use of biomarkers for routine screening 
of CSVD is not recommended in healthy populations. These 
markers may be incidental, and their significance and progres-
sion remain unclear. Several of these biomarkers, such as homo-
cysteine are not entirely specific for CSVD and can be elevated in 
other stroke subtypes.186 Moreover, interpretation of cut off val-
ues and heterogeneity among studies confounds interpretation 
of results. Future efforts should be aimed at identifying specific 
markers for asymptomatic CSVD, markers that represent acceler-
ated CSVD progression, and markers that predict conversion 
from asymptomatic to symptomatic CSVD.
Treatment and future directions
It remains unclear how to best identify patients with asymp-
tomatic CSVD. Furthermore, it is unclear whether treatment of 
CSVD at an asymptomatic disease stage is necessary or benefi-
cial.173 Perhaps the most available data comes from studies on 
WMH in community-dwelling individuals. As hypertension 
seems to play the biggest role in CSVD pathogenesis, it is not 
surprising that the majority of these studies focus on hyperten-
sion reduction. Early trials have demonstrated higher WMH 
volumes in patients with uncontrolled hypertension compared 
to those receiving antihypertensive medications.187,188 Further-
more, several trials have demonstrated reduced WMH progres-
sion with BP reduction therapy,189-193 although these results 
were not replicated in all studies.194 When these trials were an-
alyzed in a recent meta-analysis,193 less WMH progression was 
observed in subjects taking antihypertensive medications. The 
optimal timing for usage of these antihypertensives remains 
unclear, but presumably, earlier intervention may be more ben-
eficial. Whether antihypertensive medications have similar ef-
fects on other CSVD biomarkers in unknown. 
In addition to antihypertensives, other studies have exam-
ined statin usage, although very few population-based studies 
demonstrate an association of hyperlipidemia with CSVD. Three 
studies have demonstrated reductions in WMH with lipid-low-
ering drugs,195-197 while other studies did not show any bene-
fit.198,199 Although the association between diabetes and CSVD 
is controversial,200,201 hyperglycemia was shown to influence 
WMH progression in one study.72 No studies, however, have 
evaluated glycemic control on WMH reduction. Lastly, in one 
meta-analysis, half of the studies demonstrated WMH reduc-
tion with exercise, but the other half did not.202
Although antiplatelet agents have been extensively evaluated 
in the primary and secondary prevention of patients with lacu-
nar stroke, there have been few studies examining the cerebro-
vascular effects of antiplatelet agents in healthy populations. In 
one small study, healthy subjects who underwent MRI screening 
for WMH were given antiplatelet therapy.203,204 In a follow-up 
MRI study 5 years later, there was no difference in deep or peri-
ventricular WMH progression among patients taking antiplate-
let agents. Given the small observational nature of this study, 
larger studies will need to be performed to fully elucidate the 
effects of antiplatelet therapy on CSVD prevention. However, it 
should be noted that these therapies may be counterbalanced 
by an increased risk of CMB (and subsequent ICH).205,206
Some patients with CSVD may exhibit minimal or no clinical 
symptoms while other patients develop stroke, cognitive im-
pairment, and other long-term morbidity.6,7,27 Early detection of 
clinically significant CSVD is particularly difficult for reasons 
including (1) utility of screening in the general population and 
(2) lack of full understanding of the significance of CSVD bio-
markers.207 Part of the challenge in developing a validated brain 
biomarker for CSVD is the complex pathways that underlie the 
disease. Risk prediction models to select populations at higher 
risk are urgently needed.
Disclosure
The authors have no financial conflicts of interest.
Acknowledgments
This work was supported by the National Institutes of Health 
(R01AG047975, R01AG026484, P50AG005134, and K23AG028 
72605 to AV and R25NS065743 to RWR).
References
1. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lings-
ma HF, Yoo AJ, et al. A randomized trial of intraarterial treat-
ment for acute ischemic stroke. N Engl J Med 2015;372:11-20.
2. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi 
N, et al. Endovascular therapy for ischemic stroke with perfu-
sion-imaging selection. N Engl J Med 2015;372:1009-1018. 
3. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, 
Rovira A, et al. Thrombectomy within 8 hours after symptom 
onset in ischemic stroke. N Engl J Med 2015;372:2296-2306. 
4. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, 
et al. Stent-retriever thrombectomy after intravenous t-PA 
vs. t-PA alone in stroke. N Engl J Med 2015;372:2285-2295. 
5. Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, 
Moulin T, et al. Mechanical thrombectomy after intravenous 
alteplase versus alteplase alone after stroke (THRACE): a ran-
Vol. 21 / No. 2 / May 2019
https://doi.org/10.5853/jos.2018.03608 http://j-stroke.org 131
domised controlled trial. Lancet Neurol 2016;15:1138-1147. 
6. Charidimou A, Pantoni L, Love S. The concept of sporadic ce-
rebral small vessel disease: a road map on key definitions 
and current concepts. Int J Stroke 2016;11:6-18.
7. Pantoni L. Cerebral small vessel disease: from pathogenesis 
and clinical characteristics to therapeutic challenges. Lancet 
Neurol 2010;9:689-701. 
8. Whitman GT, Tang Y, Lin A, Baloh RW. A prospective study of 
cerebral white matter abnormalities in older people with gait 
dysfunction. Neurology 2001;57:990-994. 
9. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, 
Breteler MM. Silent brain infarcts and the risk of dementia 
and cognitive decline. N Engl J Med 2003;348:1215-1222.
10. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain in-
farcts: a systematic review. Lancet Neurol 2007;6:611-619. 
11. Russo E, Leo A, Scicchitano F, Donato A, Ferlazzo E, Gasparini 
S, et al. Cerebral small vessel disease predisposes to temporal 
lobe epilepsy in spontaneously hypertensive rats. Brain Res 
Bull 2017;130:245-250.
12. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, 
Jolles J, et al. Cerebral white matter lesions and cognitive 
function: the Rotterdam Scan Study. Ann Neurol 2000;47: 
145-151.
13. van der Holst HM, van Uden IW, Tuladhar AM, de Laat KF, 
van Norden AG, Norris DG, et al. Cerebral small vessel dis-
ease and incident parkinsonism: The RUN DMC study. Neu-
rology 2015;85:1569-1577. 
14. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic 
cerebral small vessel disease: insights from neuroimaging. 
Lancet Neurol 2013;12:483-497. 
15. Søndergaard CB, Nielsen JE, Hansen CK, Christensen H. He-
reditary cerebral small vessel disease and stroke. Clin Neurol 
Neurosurg 2017;155:45-57. 
16. Choi JC. Genetics of cerebral small vessel disease. J Stroke 
2015;17:7-16.
17. Wermer MJH, Greenberg SM. The growing clinical spectrum 
of cerebral amyloid angiopathy. Curr Opin Neurol 2018;31: 
28-35. 
18. Charidimou A, Boulouis G, Gurol ME, Ayata C, Bacskai BJ, 
Frosch MP, et al. Emerging concepts in sporadic cerebral am-
yloid angiopathy. Brain 2017;140:1829-1850.
19. Greenberg SM. Small vessels, big problems. N Engl J Med 
2006;354:1451-1453.
20. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, 
Frayne R, et al. Neuroimaging standards for research into 
small vessel disease and its contribution to ageing and neu-
rodegeneration. Lancet Neurol 2013;12:822-838. 
21. Price TR, Manolio TA, Kronmal RA, Kittner SJ, Yue NC, Robbins 
J, et al. Silent brain infarction on magnetic resonance imag-
ing and neurological abnormalities in community-dwelling 
older adults. The Cardiovascular Health Study. CHS Collabora-
tive Research Group. Stroke 1997;28:1158-1164.
22. Leary MC, Saver JL. Annual incidence of first silent stroke in 
the United States: a preliminary estimate. Cerebrovasc Dis 
2003;16:280-285.
23. Westover MB, Bianchi MT, Yang C, Schneider JA, Greenberg 
SM. Estimating cerebral microinfarct burden from autopsy 
samples. Neurology 2013;80:1365-1369. 
24. Auriel E, Westover MB, Bianchi MT, Reijmer Y, Martinez-
Ramirez S, Ni J, et al. Estimating total cerebral microinfarct 
burden from diffusion-weighted imaging. Stroke 2015;46: 
2129-2135. 
25. van Veluw SJ, Shih AY, Smith EE, Chen C, Schneider JA, 
Wardlaw JM, et al. Detection, risk factors, and functional 
consequences of cerebral microinfarcts. Lancet Neurol 2017; 
16:730-740. 
26. Feng C, Bai X, Xu Y, Hua T, Liu XY. The ‘silence’ of silent brain 
infarctions may be related to chronic ischemic precondition-
ing and nonstrategic locations rather than to a small infarc-
tion size. Clinics (Sao Paulo) 2013;68:365-369.
27. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a 
dynamic whole-brain disease. Stroke Vasc Neurol 2016;1:83-
92.
28. van Leijsen EMC, de Leeuw FE, Tuladhar AM. Disease progres-
sion and regression in sporadic small vessel disease-insights 
from neuroimaging. Clin Sci (Lond) 2017;131:1191-1206.
29. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neu-
rol 1987;44:21-23.
30. Pantoni L, Garcia JH. The significance of cerebral white mat-
ter abnormalities 100 years after Binswanger’s report: a re-
view. Stroke 1995;26:1293-1301.
31. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. 
Stroke 1997;28:652-659.
32. Debette S, Markus HS. The clinical importance of white mat-
ter hyperintensities on brain magnetic resonance imaging: 
systematic review and meta-analysis. BMJ 2010;341:c3666. 
33. Topakian R, Barrick TR, Howe FA, Markus HS. Blood-brain 
barrier permeability is increased in normal-appearing white 
matter in patients with lacunar stroke and leucoaraiosis. J 
Neurol Neurosurg Psychiatry 2010;81:192-197. 
34. Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S. What 
are white matter hyperintensities made of? Relevance to vas-
cular cognitive impairment. J Am Heart Assoc 2015;4:001140.
35. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, 
Jungreis CA, et al. Clinical correlates of white matter findings 
on cranial magnetic resonance imaging of 3301 elderly people. 
Das et al.  Asymptomatic Cerebral Small Vessel Disease
https://doi.org/10.5853/jos.2018.03608132 http://j-stroke.org
The Cardiovascular Health Study. Stroke 1996;27:1274-1282. 
36. Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr, Manolio TA, 
Lefkowitz D, Jungreis C, et al. Incidence, manifestations, and 
predictors of worsening white matter on serial cranial mag-
netic resonance imaging in the elderly: the Cardiovascular 
Health Study. Stroke 2005;36:56-61.
37. de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, 
Heijboer R, et al. Prevalence of cerebral white matter lesions 
in elderly people: a population based magnetic resonance 
imaging study. The Rotterdam Scan Study. J Neurol Neuro-
surg Psychiatry 2001;70:9-14. 
38. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, 
Breteler MM. Progression of cerebral small vessel disease in 
relation to risk factors and cognitive consequences: Rotter-
dam Scan study. Stroke 2008;39:2712-2719.
39. Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Hutchinson RG, et 
al. Presence and severity of cerebral white matter lesions and 
hypertension, its treatment, and its control. The ARIC Study. 
Atherosclerosis Risk in Communities Study. Stroke 1996;27: 
2262-2270.
40. Schmidt R, Fazekas F, Kapeller P, Schmidt H, Hartung HP. MRI 
white matter hyperintensities: three-year follow-up of the 
Austrian Stroke Prevention Study. Neurology 1999;53:132-
139. 
41. Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt 
H, et al. White matter lesion progression, brain atrophy, and 
cognitive decline: the Austrian Stroke Prevention Study. Ann 
Neurol 2005;58:610-616. 
42. Power MC, Deal JA, Sharrett AR, Jack CR Jr, Knopman D, Mos-
ley TH, et al. Smoking and white matter hyperintensity pro-
gression: the ARIC-MRI Study. Neurology 2015;84:841-848. 
43. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, 
D’Agostino RB, et al. Stroke risk profile predicts white matter 
hyperintensity volume: the Framingham Study. Stroke 2004; 
35:1857-1861.
44. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, 
et al. Midlife vascular risk factor exposure accelerates struc-
tural brain aging and cognitive decline. Neurology 2011;77: 
461-468. 
45. Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F. Pro-
gression of leukoaraiosis and cognition. Stroke 2007;38: 
2619-2625.
46. Bokura H, Kobayashi S, Yamaguchi S, Iijima K, Nagai A, Toyoda 
G, et al. Silent brain infarction and subcortical white matter 
lesions increase the risk of stroke and mortality: a prospective 
cohort study. J Stroke Cerebrovasc Dis 2006;15:57-63.
47. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kro-
nmal RA, et al. The Cardiovascular Health Study: design and 
rationale. Ann Epidemiol 1991;1:263-276.
48. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, 
Borhani NO. Recruitment of adults 65 years and older as 
participants in the Cardiovascular Health Study. Ann Epide-
miol 1993;3:358-366.
49. Price TR, Psaty B, O’Leary D, Burke G, Gardin J. Assessment of 
cerebrovascular disease in the Cardiovascular Health Study. 
Ann Epidemiol 1993;3:504-507.
50. Manolio TA, Kronmal RA, Burke GL, Poirier V, O’Leary DH, 
Gardin JM, et al. Magnetic resonance abnormalities and car-
diovascular disease in older adults. The Cardiovascular Health 
Study. Stroke 1994;25:318-327.
51. Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis 
CA, Price TR. Lacunar infarcts defined by magnetic resonance 
imaging of 3660 elderly people: the Cardiovascular Health 
Study. Arch Neurol 1998;55:1217-1225. 
52. Bernick C, Kuller L, Dulberg C, Longstreth WT Jr, Manolio T, 
Beauchamp N, et al. Silent MRI infarcts and the risk of future 
stroke: the Cardiovascular Health Study. Neurology 2001;57: 
1222-1229.
53. Longstreth WT Jr, Dulberg C, Manolio TA, Lewis MR, Beau-
champ NJ Jr, O’Leary D, et al. Incidence, manifestations, and 
predictors of brain infarcts defined by serial cranial magnetic 
resonance imaging in the elderly: the Cardiovascular Health 
Study. Stroke 2002;33:2376-2382.
54. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. 
Determinants of disease and disability in the elderly: the 
Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-422.
55. van Dijk EJ, Prins ND, Vermeer SE, Koudstaal PJ, Breteler MM. 
Frequency of white matter lesions and silent lacunar infarcts. 
J Neural Transm Suppl 2002;62:25-39.
56. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler 
MM. Prevalence and risk factors of silent brain infarcts in the 
population-based Rotterdam Scan Study. Stroke 2002;33:21-
25. 
57. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, 
Krestin GP, et al. Incidental findings on brain MRI in the gen-
eral population. N Engl J Med 2007;357:1821-1828.
58. Poels MM, Zaccai K, Verwoert GC, Vernooij MW, Hofman A, 
van der Lugt A, et al. Arterial stiffness and cerebral small 
vessel disease: the Rotterdam Scan Study. Stroke 2012;43: 
2637-2642. 
59. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, 
Buckley BM, et al. The design of a prospective study of 
Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study 
Group. PROspective Study of Pravastatin in the Elderly at 
Risk. Am J Cardiol 1999;84:1192-1197.
60. van den Heuvel DM, Admiraal-Behloul F, ten Dam VH, Olof-
Vol. 21 / No. 2 / May 2019
https://doi.org/10.5853/jos.2018.03608 http://j-stroke.org 133
sen H, Bollen EL, Murray HM, et al. Different progression 
rates for deep white matter hyperintensities in elderly men 
and women. Neurology 2004;63:1699-1701.
61. The ARIC investigators. The Atherosclerosis Risk in Commu-
nities (ARIC) study: design and objectives. Am J Epidemiol 
1989;129:687-702. 
62. Mosley TH Jr, Knopman DS, Catellier DJ, Bryan N, Hutchinson 
RG, Grothues CA, et al. Cerebral MRI findings and cognitive 
functioning: the Atherosclerosis Risk in Communities study. 
Neurology 2005;64:2056-2062. 
63. Liao D, Cooper L, Cai J, Toole J, Bryan N, Burke G, et al. The 
prevalence and severity of white matter lesions, their rela-
tionship with age, ethnicity, gender, and cardiovascular dis-
ease risk factors: the ARIC Study. Neuroepidemiology 1997; 
16:149-162.
64. Gottesman RF, Coresh J, Catellier DJ, Sharrett AR, Rose KM, 
Coker LH, et al. Blood pressure and white-matter disease 
progression in a biethnic cohort: Atherosclerosis Risk in 
Communities (ARIC) study. Stroke 2010;41:3-8.
65. Wolma J, Nederkoorn PJ, Goossens A, Vergouwen MD, van 
Schaik IN, Vermeulen M. Ethnicity a risk factor? The relation 
between ethnicity and large- and small-vessel disease in 
White people, Black people, and Asians within a hospital-
based population. Eur J Neurol 2009;16:522-527. 
66. Hilal S, Mok V, Youn YC, Wong A, Ikram MK, Chen CL. Preva-
lence, risk factors and consequences of cerebral small vessel 
diseases: data from three Asian countries. J Neurol Neurosurg 
Psychiatry 2017;88:669-674. 
67. Sudre CH, Smith L, Atkinson D, Chaturvedi N, Ourselin S, Bark-
hof F, et al. Cardiovascular risk factors and white matter hy-
perintensities: difference in susceptibility in south Asians 
compared with Europeans. J Am Heart Assoc 2018;7:e010533. 
68. Han F, Zhai FF, Wang Q, Zhou LX, Ni J, Yao M, et a. Prevalence 
and risk factors of cerebral small vessel disease in a Chinese 
population-based sample. J Stroke 2018;20:239-246. 
69. van Zagten M, Boiten J, Kessels F, Lodder J. Significant pro-
gression of white matter lesions and small deep (lacunar) in-
farcts in patients with stroke. Arch Neurol 1996;53:650-655.
70. Sachdev P, Wen W, Chen X, Brodaty H. Progression of white 
matter hyperintensities in elderly individuals over 3 years. 
Neurology 2007;68:214-222.
71. Wahlund LO, Almkvist O, Basun H, Julin P. MRI in successful 
aging, a 5-year follow-up study from the eighth to ninth de-
cade of life. Magn Reson Imaging 1996;14:601-608. 
72. Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pan-
toni L, Poggesi A, et al. Progression of white matter hyperin-
tensities and incidence of new lacunes over a 3-year period: 
the Leukoaraiosis and Disability study. Stroke 2008;39:1414-
1420.
73. Taylor WD, MacFall JR, Provenzale JM, Payne ME, McQuoid 
DR, Steffens DC, et al. Serial MR imaging of volumes of hy-
perintense white matter lesions in elderly patients: correla-
tion with vascular risk factors. AJR Am J Roentgenol 2003; 
181:571-576.
74. Kuller LH, Longstreth WT Jr, Arnold AM, Bernick C, Bryan RN, 
Beauchamp NJ Jr, et al. White matter hyperintensity on cra-
nial magnetic resonance imaging: a predictor of stroke. 
Stroke 2004;35:1821-1825. 
75. Schmidt R, Fazekas F, Enzinger C, Ropele S, Kapeller P, 
Schmidt H. Risk factors and progression of small vessel dis-
ease-related cerebral abnormalities. J Neural Transm Suppl 
2002;62:47-52. 
76. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F; Aus-
trian Stroke Prevention Study. Progression of cerebral white 
matter lesions: 6-year results of the Austrian Stroke Preven-
tion Study. Lancet 2003;361:2046-2048.
77. Verhaaren BF, Vernooij MW, de Boer R, Hofman A, Niessen 
WJ, van der Lugt A, et al. High blood pressure and cerebral 
white matter lesion progression in the general population. 
Hypertension 2013;61:1354-1359. 
78. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, Kelly-Hayes M, 
et al. Association of MRI markers of vascular brain injury with 
incident stroke, mild cognitive impairment, dementia, and 
mortality: the Framingham Offspring Study. Stroke 2010;41: 
600-606. 
79. Ikram MA, Vernooij MW, Vrooman HA, Hofman A, Breteler 
MM. Brain tissue volumes and small vessel disease in relation 
to the risk of mortality. Neurobiol Aging 2009;30:450-456.
80. Kerber KA, Whitman GT, Brown DL, Baloh RW. Increased risk 
of death in community-dwelling older people with white 
matter hyperintensities on MRI. J Neurol Sci 2006;250:33-38.
81. Buyck JF, Dufouil C, Mazoyer B, Maillard P, Ducimetière P, 
Alpérovitch A, et al. Cerebral white matter lesions are associ-
ated with the risk of stroke but not with other vascular 
events: the 3-City Dijon Study. Stroke 2009;40:2327-2331.
82. Tully PJ, Debette S, Mazoyer B, Tzourio C. White matter le-
sions are associated with specific depressive symptom tra-
jectories among incident depression and dementia popula-
tions: three-city Dijon MRI study. Am J Geriatr Psychiatry 
2017;25:1311-1321.
83. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, 
Dickerson BC, et al. Magnetic resonance imaging white mat-
ter hyperintensities and brain volume in the prediction of 
mild cognitive impairment and dementia. Arch Neurol 2008; 
65:94-100. 
84. Silbert LC, Howieson DB, Dodge H, Kaye JA. Cognitive impair-
Das et al.  Asymptomatic Cerebral Small Vessel Disease
https://doi.org/10.5853/jos.2018.03608134 http://j-stroke.org
ment risk: white matter hyperintensity progression matters. 
Neurology 2009;73:120-125.
85. van den Heuvel DM, ten Dam VH, de Craen AJ, Admiraal-
Behloul F, Olofsen H, Bollen EL, et al. Increase in periventric-
ular white matter hyperintensities parallels decline in mental 
processing speed in a non-demented elderly population. J 
Neurol Neurosurg Psychiatry 2006;77:149-153. 
86. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, 
Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E 
type 4 allele and the risk of Alzheimer’s disease in late onset 
families. Science 1993;261:921-923.
87. Heise V, Filippini N, Ebmeier KP, Mackay CE. The APOE ɛ4 al-
lele modulates brain white matter integrity in healthy adults. 
Mol Psychiatry 2011;16:908-916.
88. Sudre CH, Cardoso MJ, Frost C, Barnes J, Barkhof F, Fox N, et 
al. APOE ε4 status is associated with white matter hyperin-
tensities volume accumulation rate independent of AD diag-
nosis. Neurobiol Aging 2017;53:67-75.
89. Cox SR, Ritchie SJ, Dickie DA, Pattie A, Royle NA, Corley J, et 
al. Interaction of APOE e4 and poor glycemic control predicts 
white matter hyperintensity growth from 73 to 76. Neurobiol 
Aging 2017;54:54-58.
90. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, 
Oudkerk M, et al. Cerebral white matter lesions and the risk 
of dementia. Arch Neurol 2004;61:1531-1534.
91. Fisher CM. Lacunar strokes and infarcts: a review. Neurology 
1982;32:871-876.
92. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology 
1965;15:774-784.
93. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, 
Smith EE, et al. Silent ischemic infarcts are associated with 
hemorrhage burden in cerebral amyloid angiopathy. Neurol-
ogy 2009;72:1230-1235. 
94. Prabhakaran S, Gupta R, Ouyang B, John S, Temes RE, Mo-
hammad Y, et al. Acute brain infarcts after spontaneous in-
tracerebral hemorrhage: a diffusion-weighted imaging study. 
Stroke 2010;41:89-94. 
95. Wardlaw JM, Chappell FM, Valdés Hernández MDC, Makin 
SDJ, Staals J, Shuler K, et al. White matter hyperintensity re-
duction and outcomes after minor stroke. Neurology 2017;89: 
1003-1010. 
96. Moreau F, Patel S, Lauzon ML, McCreary CR, Goyal M, Frayne 
R, et al. Cavitation after acute symptomatic lacunar stroke 
depends on time, location, and MRI sequence. Stroke 2012; 
43:1837-1842.
97. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent 
brain infarction: a systematic review of population-based 
cohorts. BMC Med 2014;12:119.
98. Howard G, Wagenknecht LE, Cai J, Cooper L, Kraut MA, Toole 
JF. Cigarette smoking and other risk factors for silent cerebral 
infarction in the general population. Stroke 1998;29:913-917.
99. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, 
Breteler MM, et al. Incidence and risk factors of silent brain 
infarcts in the population-based Rotterdam Scan Study. Stroke 
2003;34:392-396.
100. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal 
PJ, Breteler MM, et al. Silent brain infarcts and white matter 
lesions increase stroke risk in the general population: the 
Rotterdam Scan Study. Stroke 2003;34:1126-1129.
101. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, 
Al-Shahi Salman R, Warach S, et al. Cerebral microbleeds: a 
guide to detection and interpretation. Lancet Neurol 2009; 
8:165-174.
102. Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral 
microbleeds: overview and implications in cognitive impair-
ment. Alzheimers Res Ther 2014;6:33.
103. Shoamanesh A, Kwok CS, Benavente O. Cerebral microbleeds: 
histopathological correlation of neuroimaging. Cerebrovasc 
Dis 2011;32:528-534.
104. Viswanathan A, Chabriat H. Cerebral microhemorrhage. 
Stroke 2006;37:550-555.
105. Tsushima Y, Tanizaki Y, Aoki J, Endo K. MR detection of mi-
crohemorrhages in neurologically healthy adults. Neuroradi-
ology 2002;44:31-36.
106. Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin GP, 
van der Lugt A, et al. Prevalence and risk factors of cerebral 
microbleeds: an update of the Rotterdam scan study. Stroke 
2010;41:S103-S106. 
107. Roob G, Schmidt R, Kapeller P, Lechner A, Hartung HP, Faze-
kas F. MRI evidence of past cerebral microbleeds in a healthy 
elderly population. Neurology 1999;52:991-994.
108. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological ap-
proaches to heart disease: the Framingham Study. Am J Pub-
lic Health Nations Health 1951;41:279-281.
109. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli 
WP. An investigation of coronary heart disease in families. 
The Framingham offspring study. Am J Epidemiol 1979;110: 
281-290. 
110. Sveinbjornsdottir S, Sigurdsson S, Aspelund T, Kjartansson O, 
Eiriksdottir G, Valtysdottir B, et al. Cerebral microbleeds in 
the population based AGES-Reykjavik study: prevalence and 
location. J Neurol Neurosurg Psychiatry 2008;79:1002-1006.
111. Del Brutto VJ, Zambrano M, Mera RM, Del Brutto OH. Popu-
lation-based study of cerebral microbleeds in stroke-free 
older adults living in rural Ecuador: The Atahualpa Project. 
Stroke 2015;46:1984-1986.
Vol. 21 / No. 2 / May 2019
https://doi.org/10.5853/jos.2018.03608 http://j-stroke.org 135
112. de Laat KF, van den Berg HA, van Norden AG, Gons RA, Olde 
Rikkert MG, de Leeuw FE. Microbleeds are independently re-
lated to gait disturbances in elderly individuals with cerebral 
small vessel disease. Stroke 2011;42:494-497.
113. Mitaki S, Nagai A, Oguro H, Yamaguchi S. Serum lipid frac-
tions and cerebral microbleeds in a healthy Japanese popu-
lation. Cerebrovasc Dis 2017;43:186-191. 
114. Mok V, Srikanth V, Xiong Y, Phan TG, Moran C, Chu S, et al. 
Race-ethnicity and cerebral small vessel disease: comparison 
between Chinese and White populations. Int J Stroke 2014;9 
Suppl A100:36-42. 
115. Jeerakathil T, Wolf PA, Beiser A, Hald JK, Au R, Kase CS, et al. 
Cerebral microbleeds: prevalence and associations with car-
diovascular risk factors in the Framingham Study. Stroke 
2004;35:1831-1835.
116. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, 
Niessen WJ, Hofman A, et al. Prevalence and risk factors of 
cerebral microbleeds: the Rotterdam Scan Study. Neurology 
2008;70:1208-1214. 
117. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, 
Sigurdsson G, et al. Age, Gene/Environment Susceptibility-
Reykjavik Study: multidisciplinary applied phenomics. Am J 
Epidemiol 2007;165:1076-1087. 
118. Akoudad S, Portegies ML, Koudstaal PJ, Hofman A, van der 
Lugt A, Ikram MA, et al. Cerebral microbleeds are associated 
with an increased risk of stroke: the Rotterdam Study. Circu-
lation 2015;132:509-516.
119. Song TJ, Kim J, Kim YD, Nam HS, Lee HS, Nam CM, et al. The 
distribution of cerebral microbleeds determines their associ-
ation with arterial stiffness in non-cardioembolic acute 
stroke patients. Eur J Neurol 2014;21:463-469.
120. Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin 
GP, Stricker BH, et al. Use of antithrombotic drugs and the 
presence of cerebral microbleeds: the Rotterdam Scan Study. 
Arch Neurol 2009;66:714-720. 
121. Kakar P, Charidimou A, Werring DJ. Cerebral microbleeds: a 
new dilemma in stroke medicine. JRSM Cardiovasc Dis 2012; 
1:2048004012474754. 
122. Altmann-Schneider I, Trompet S, de Craen AJ, van Es AC, 
Jukema JW, Stott DJ, et al. Cerebral microbleeds are predic-
tive of mortality in the elderly. Stroke 2011;42:638-644.
123. van Es AC, van der Grond J, de Craen AJ, Westendorp RG, 
Bollen EL, Blauw GJ, et al. Cerebral microbleeds and cogni-
tive functioning in the PROSPER study. Neurology 2011;77: 
1446-1452.
124. Choi P, Ren M, Phan TG, Callisaya M, Ly JV, Beare R, et al. Si-
lent infarcts and cerebral microbleeds modify the associa-
tions of white matter lesions with gait and postural stability: 
population-based study. Stroke 2012;43:1505-1510.
125. Qiu C, Cotch MF, Sigurdsson S, Jonsson PV, Jonsdottir MK, 
Sveinbjrnsdottir S, et al. Cerebral microbleeds, retinopathy, and 
dementia: the AGES-Reykjavik Study. Neurology 2010;75: 
2221-2228.
126. Akoudad S, Wolters FJ, Viswanathan A, de Bruijn RF, van der 
Lugt A, Hofman A, et al. Association of cerebral microbleeds 
with cognitive decline and dementia. JAMA Neurol 2016;73: 
934-943.
127. Romero JR, Beiser A, Himali JJ, Shoamanesh A, DeCarli C, Ses-
hadri S. Cerebral microbleeds and risk of incident dementia: 
the Framingham Heart Study. Neurobiol Aging 2017;54:94-99.
128. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. 
Symposium: clearance of Aβ from the brain in Alzheimer’s 
disease: perivascular drainage of amyloid‐β peptides from 
the brain and its failure in cerebral amyloid angiopathy and 
Alzheimer’s disease. Brain Pathol 2008;18:253-266. 
129. Charidimou A, Meegahage R, Fox Z, Peeters A, Vandermeeren 
Y, Laloux P, et al. Enlarged perivascular spaces as a marker of 
underlying arteriopathy in intracerebral haemorrhage: a 
multicentre MRI cohort study. J Neurol Neurosurg Psychiatry 
2013;84:624-629. 
130. Martinez-Ramirez S, Pontes-Neto OM, Dumas AP, Auriel E, 
Halpin A, Quimby M, et al. Topography of dilated perivascu-
lar spaces in subjects from a memory clinic cohort. Neurolo-
gy 2013;80:1551-1556.
131. Yakushiji Y, Charidimou A, Hara M, Noguchi T, Nishihara M, 
Eriguchi M, et al. Topography and associations of perivascu-
lar spaces in healthy adults: the Kashima scan study. Neurol-
ogy 2014;83:2116-2123.
132. Zhu YC, Dufouil C, Mazoyer B, Soumaré A, Ricolfi F, Tzourio 
C, et al. Frequency and location of dilated Virchow-Robin 
spaces in elderly people: a population-based 3D MR imaging 
study. AJNR Am J Neuroradiol 2011;32:709-713. 
133. Ramirez J, Berezuk C, McNeely AA, Scott CJ, Gao F, Black SE. 
Visible Virchow-Robin spaces on magnetic resonance imag-
ing of Alzheimer’s disease patients and normal elderly from 
the Sunnybrook Dementia Study. J Alzheimers Dis 2015;43: 
415-424.
134. Zhu YC, Tzourio C, Soumaré A, Mazoyer B, Dufouil C, Chabriat 
H. Severity of dilated Virchow-Robin spaces is associated with 
age, blood pressure, and MRI markers of small vessel disease: 
a population-based study. Stroke 2010;41:2483-2490.
135. Bokura H, Kobayashi S, Yamaguchi S. Distinguishing silent 
lacunar infarction from enlarged Virchow-Robin spaces: a 
magnetic resonance imaging and pathological study. J Neu-
rol 1998;245:116-122.
136. Ding J, Sigurðsson S, Jónsson PV, Eiriksdottir G, Charidimou A, 
Das et al.  Asymptomatic Cerebral Small Vessel Disease
https://doi.org/10.5853/jos.2018.03608136 http://j-stroke.org
Lopez OL, et al. Large perivascular spaces visible on magnetic 
resonance imaging, cerebral small vessel disease progression, 
and risk of dementia: the Age, Gene/Environment Susceptibil-
ity-Reykjavik Study. JAMA Neurol 2017;74:1105-1112.
137. Maclullich AM, Wardlaw JM, Ferguson KJ, Starr JM, Seckl JR, 
Deary IJ. Enlarged perivascular spaces are associated with 
cognitive function in healthy elderly men. J Neurol Neurosurg 
Psychiatry 2004;75:1519-1523.
138. Patankar TF, Mitra D, Varma A, Snowden J, Neary D, Jackson 
A. Dilatation of the Virchow-Robin space is a sensitive indica-
tor of cerebral microvascular disease: study in elderly patients 
with dementia. AJNR Am J Neuroradiol 2005;26:1512-1520.
139. Arba F, Quinn TJ, Hankey GJ, Lees KR, Wardlaw JM, Ali M, et 
al. Enlarged perivascular spaces and cognitive impairment 
after stroke and transient ischemic attack. Int J Stroke 
2018;13:47-56. 
140. Zhu YC, Dufouil C, Soumaré A, Mazoyer B, Chabriat H, Tzou-
rio C. High degree of dilated Virchow-Robin spaces on MRI is 
associated with increased risk of dementia. J Alzheimers Dis 
2010;22:663-672.
141. Vernooij MW, Ikram MA, Hofman A, Krestin GP, Breteler MM, 
van der Lugt A. Superficial siderosis in the general popula-
tion. Neurology 2009;73:202-205.
142. Charidimou A, Linn J, Vernooij MW, Opherk C, Akoudad S, 
Baron JC, et al. Cortical superficial siderosis: detection and 
clinical significance in cerebral amyloid angiopathy and re-
lated conditions. Brain 2015;138:2126-2139.
143. Pichler M, Vemuri P, Rabinstein AA, Aakre J, Flemming KD, 
Brown RD Jr, et al. Prevalence and natural history of superfi-
cial siderosis: a population-based study. Stroke 2017;48: 
3210-3214.
144. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Bo-
eve BF, et al. The Mayo Clinic study of aging: design and 
sampling, participation, baseline measures and sample char-
acteristics. Neuroepidemiology 2008;30:58-69. 
145. Shoamanesh A, Martinez-Ramirez S, Oliveira-Filho J, Reijmer 
Y, Falcone GJ, Ayres A, et al. Interrelationship of superficial 
siderosis and microbleeds in cerebral amyloid angiopathy. 
Neurology 2014;83:1838-1843.
146. Charidimou A, Martinez-Ramirez S, Shoamanesh A, Oliveira-
Filho J, Frosch M, Vashkevich A, et al. Cerebral amyloid angi-
opathy with and without hemorrhage: evidence for different 
disease phenotypes. Neurology 2015;84:1206-1212.
147. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral 
microinfarcts: the invisible lesions. Lancet Neurol 2012;11: 
272-282.
148. Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ. 
Cerebral microinfarcts: a systematic review of neuropatho-
logical studies. J Cereb Blood Flow Metab 2012;32:425-436.
149. van Veluw SJ, Hilal S, Kuijf HJ, Ikram MK, Xin X, Yeow TB, et 
al. Cortical microinfarcts on 3T MRI: clinical correlates in 
memory-clinic patients. Alzheimers Dement 2015;11:1500-
1509.
150. Hilal S, Sikking E, Shaik MA, Chan QL, van Veluw SJ, Vrooman H, 
et al. Cortical cerebral microinfarcts on 3T MRI: a novel marker 
of cerebrovascular disease. Neurology 2016;87:1583-1590.
151. Jouvent E, Poupon C, Gray F, Paquet C, Mangin JF, Le Bihan D, 
et al. Intracortical infarcts in small vessel disease: a combined 
7-T postmortem MRI and neuropathological case study in ce-
rebral autosomal-dominant arteriopathy with subcortical in-
farcts and leukoencephalopathy. Stroke 2011;42:e27-e30. 
152. van Veluw SJ, Zwanenburg JJ, Engelen-Lee J, Spliet WG, 
Hendrikse J, Luijten PR, et al. In vivo detection of cerebral 
cortical microinfarcts with high-resolution 7T MRI. J Cereb 
Blood Flow Metab 2013;33:322-329. 
153. van Veluw SJ, Heringa SM, Kuijf HJ, Koek HL, Luijten PR, 
Biessels GJ, et al. Cerebral cortical microinfarcts at 7 Tesla 
MRI in patients with early Alzheimer’s disease. J Alzheimers 
Dis 2014;39:163-167.
154. van Dalen JW, Scuric EE, van Veluw SJ, Caan MW, Nederveen 
AJ, Biessels GJ, et al. Cortical microinfarcts detected in vivo 
on 3 Tesla MRI: clinical and radiological correlates. Stroke 
2015;46:255-257. 
155. Wityk RJ. Cerebral cortical microinfarcts on 3-t magnetic 
resonance imaging: a new tool in the study of cerebrovascu-
lar ischemia. JAMA Neurol 2017;74:385-386.
156. Ii Y, Maeda M, Kida H, Matsuo K, Shindo A, Taniguchi A, et 
al. In vivo detection of cortical microinfarcts on ultrahigh-
field MRI. J Neuroimaging 2013;23:28-32.
157. van Rooden S, Goos JD, van Opstal AM, Versluis MJ, Webb 
AG, Blauw GJ, et al. Increased number of microinfarcts in Al-
zheimer disease at 7-T MR imaging. Radiology 2014;270: 
205-211.
158. Fu R, Wang Y, Wang Y, Liu L, Zhao X, Wang DZ, et al. The de-
velopment of cortical microinfarcts is associated with intra-
cranial atherosclerosis: data from the Chinese intracranial 
atherosclerosis study. J Stroke Cerebrovasc Dis 2015;24: 
2447-2454.
159. Longstreth WT Jr, Sonnen JA, Koepsell TD, Kukull WA, Larson 
EB, Montine TJ. Associations between microinfarcts and oth-
er macroscopic vascular findings on neuropathologic exami-
nation in 2 databases. Alzheimer Dis Assoc Disord 2009;23: 
291-294.
160. Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick W, 
Bowen JD, et al. Blood pressure and brain injury in older 
adults: findings from a community-based autopsy study. J 
Vol. 21 / No. 2 / May 2019
https://doi.org/10.5853/jos.2018.03608 http://j-stroke.org 137
Am Geriatr Soc 2009;57:1975-1981. 
161. Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova 
O, O’Brien RJ. Effect of infarcts on dementia in the Baltimore 
longitudinal study of aging. Ann Neurol 2008;64:168-176.
162. Hilal S, Chai YL, van Veluw S, Shaik MA, Ikram MK, Venketa-
subramanian N, et al. Association between subclinical cardiac 
biomarkers and clinically manifest cardiac diseases with cor-
tical cerebral microinfarcts. JAMA Neurol 2017;74:403-410.
163. Zheng L, Vinters HV, Mack WJ, Zarow C, Ellis WG, Chui HC. 
Cerebral atherosclerosis is associated with cystic infarcts and 
microinfarcts but not Alzheimer pathologic changes. Stroke 
2013;44:2835-2841. 
164. Rosman M, Zheng Y, Wong W, Lamoureux E, Saw SM, Tay 
WT, et al. Singapore Malay Eye Study: rationale and method-
ology of 6-year follow-up study (SiMES-2). Clin Exp Oph-
thalmol 2012;40:557-568. 
165. Hilal S, Ikram MK, Saini M, Tan CS, Catindig JA, Dong YH, et 
al. Prevalence of cognitive impairment in Chinese: epidemi-
ology of dementia in Singapore study. J Neurol Neurosurg 
Psychiatry 2013;84:686-692.
166. Brundel M, Reijmer YD, van Veluw SJ, Kuijf HJ, Luijten PR, 
Kappelle LJ, et al. Cerebral microvascular lesions on high-
resolution 7-Tesla MRI in patients with type 2 diabetes. Dia-
betes 2014;63:3523-3529.
167. Pruzin JJ, Schneider JA, Capuano AW, Leurgans SE, Barnes LL, 
Ahima RS, et al. Diabetes, hemoglobin A1C, and regional Al-
zheimer disease and infarct pathology. Alzheimer Dis Assoc 
Disord 2017;31:41-47.
168. Yassi N, Hilal S, Lim YY, Salinas S, Kuijf H, Xia Y, et al. Cortical 
cerebral microinfarcts on 3T MRI in Alzheimer’s disease and 
mild cognitive impairment. Alzheimers Dement 2017;13(7 
Suppl):P1378-P1379. 
169. Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider 
JA. Microinfarct pathology, dementia, and cognitive systems. 
Stroke 2011;42:722-727.
170. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview 
and findings from the religious orders study. Curr Alzheimer 
Res 2012;9:628-645.
171. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, 
Wilson RS. Overview and findings from the rush Memory and 
Aging Project. Curr Alzheimer Res 2012;9:646-663.
172. Arvanitakis Z, Capuano AW, Leurgans SE, Buchman AS, Ben-
nett DA, Schneider JA. The relationship of cerebral vessel pa-
thology to brain microinfarcts. Brain Pathol 2017;27:77-85.
173. Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, 
Gorelick PB, et al. Prevention of stroke in patients with silent 
cerebrovascular disease: a scientific statement for healthcare 
professionals from the American Heart Association/American 
Stroke Association. Stroke 2017;48:e44-e71. 
174. Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. 
Stroke subtype, vascular risk factors, and total MRI brain 
small-vessel disease burden. Neurology 2014;83:1228-1234. 
175. Cuadrado-Godia E, Dwivedi P, Sharma S, Ois Santiago A, 
Roquer Gonzalez J, Balcells M, et al. Cerebral small vessel 
disease: a review focusing on pathophysiology, biomarkers, 
and machine learning strategies. J Stroke 2018;20:302-320. 
176. Lau KK, Li L, Schulz U, Simoni M, Chan KH, Ho SL, et al. Total 
small vessel disease score and risk of recurrent stroke: vali-
dation in 2 large cohorts. Neurology 2017;88:2260-2267. 
177. Poggesi A, Pasi M, Pescini F, Pantoni L, Inzitari D. Circulating 
biologic markers of endothelial dysfunction in cerebral small 
vessel disease: a review. J Cereb Blood Flow Metab 2016;36: 
72-94.
178. Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, 
Fandler S, et al. Serum neurofilament light is sensitive to active 
cerebral small vessel disease. Neurology 2017;89:2108-2114.
179. Duering M, Konieczny MJ, Tiedt S, Baykara E, Tuladhar AM, Lei-
jsen EV, et al. Serum neurofilament light chain levels are related 
to small vessel disease burden. J Stroke 2018;20:228-238.
180. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, 
Schmidt R. Markers of endothelial and hemostatic activation 
and progression of cerebral white matter hyperintensities: 
longitudinal results of the Austrian Stroke Prevention Study. 
Stroke 2005;36:1410-1414.
181. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, 
Koudstaal PJ, et al. C-reactive protein and cerebral small-ves-
sel disease: the Rotterdam Scan Study. Circulation 2005;112: 
900-905.
182. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circu-
lating IL-6 and CRP are associated with MRI findings in the 
elderly: the 3C-Dijon Study. Neurology 2012;78:720-727.
183. Rizzi L, Marques FC, Rosset I, Moriguchi EH, Picon PD, Chaves 
ML, et al. C-reactive protein and cognition are unrelated to 
leukoaraiosis. ScientificWorldJournal 2014;2014:121679.
184. Schmidt R, Schmidt H, Pichler M, Enzinger C, Petrovic K, Nie-
derkorn K, et al. C-reactive protein, carotid atherosclerosis, 
and cerebral small-vessel disease: results of the Austrian 
Stroke Prevention Study. Stroke 2006;37:2910-2916.
185. Avci AY, Lakadamyali H, Arikan S, Benli US, Kilinc M. High 
sensitivity C-reactive protein and cerebral white matter hy-
perintensities on magnetic resonance imaging in migraine 
patients. J Headache Pain 2015;16:9. 
186. Ashjazadeh N, Fathi M, Shariat A. Evaluation of homocyste-
ine level as a risk factor among patients with ischemic stroke 
and its subtypes. Iran J Med Sci 2013;38:233-239.
187. Dufouil C, de Kersaint-Gilly A, Besançon V, Levy C, Auffray E, 
Das et al.  Asymptomatic Cerebral Small Vessel Disease
https://doi.org/10.5853/jos.2018.03608138 http://j-stroke.org
Brunnereau L, et al. Longitudinal study of blood pressure and 
white matter hyperintensities: the EVA MRI cohort. Neurolo-
gy 2001;56:921-926.
188. Fukuda H, Kitani M. Differences between treated and un-
treated hypertensive subjects in the extent of periventricular 
hyperintensities observed on brain MRI. Stroke 1995;26: 
1593-1597.
189. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman 
A, van Gijn J, et al. Hypertension and cerebral white matter le-
sions in a prospective cohort study. Brain 2002;125:765-772. 
190. Firbank MJ, Wiseman RM, Burton EJ, Saxby BK, O’Brien JT, 
Ford GA. Brain atrophy and white matter hyperintensity 
change in older adults and relationship to blood pressure. 
Brain atrophy, WMH change and blood pressure. J Neurol 
2007;254:713-721.
191. Dufouil C, Chalmers J, Coskun O, Besançon V, Bousser MG, 
Guillon P, et al. Effects of blood pressure lowering on cere-
bral white matter hyperintensities in patients with stroke: 
the PROGRESS (Perindopril Protection Against Recurrent 
Stroke Study) Magnetic Resonance Imaging Substudy. Circu-
lation 2005;112:1644-1650.
192. Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. Antihy-
pertensive treatment and change in blood pressure are asso-
ciated with the progression of white matter lesion volumes: 
the Three-City (3C)-Dijon Magnetic Resonance Imaging 
Study. Circulation 2011;123:266-273. 
193. van Middelaar T, Argillander TE, Schreuder FHBM, Deinum J, 
Richard E, Klijn CJM. Effect of antihypertensive medication 
on cerebral small vessel disease: a systematic review and 
meta-analysis. Stroke 2018;49:1531-1533. 
194. Weber R, Weimar C, Blatchford J, Hermansson K, Wanke I, 
Möller-Hartmann C, et al. Telmisartan on top of antihyper-
tensive treatment does not prevent progression of cerebral 
white matter lesions in the prevention regimen for effective-
ly avoiding second strokes (PRoFESS) MRI substudy. Stroke 
2012;43:2336-2342.
195. Vuorinen M, Solomon A, Rovio S, Nieminen L, Kåreholt I, Tu-
omilehto J, et al. Changes in vascular risk factors from 
midlife to late life and white matter lesions: a 20-year fol-
low-up study. Dement Geriatr Cogn Disord 2011;31:119-125. 
196. Mok VC, Lam WW, Fan YH, Wong A, Ng PW, Tsoi TH, et al. 
Effects of statins on the progression of cerebral white matter 
lesion: post hoc analysis of the ROCAS (Regression of Cere-
bral Artery Stenosis) study. J Neurol 2009;256:750-757. 
197. Xiong Y, Wong A, Cavalieri M, Schmidt R, Chu WW, Liu X, et 
al. Prestroke statins, progression of white matter hyperinten-
sities, and cognitive decline in stroke patients with confluent 
white matter hyperintensities. Neurotherapeutics 2014;11: 
606-611.
198. ten Dam VH, van den Heuvel DM, van Buchem MA, Westen-
dorp RG, Bollen EL, Ford I, et al. Effect of pravastatin on cere-
bral infarcts and white matter lesions. Neurology 2005;64: 
1807-1809. 
199. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, 
et al. Statins and cognitive function in the elderly: the Car-
diovascular Health Study. Neurology 2005;65:1388-1394.
200. Jongen C, van der Grond J, Kappelle LJ, Biessels GJ, Viergever 
MA, Pluim JP, et al. Automated measurement of brain and 
white matter lesion volume in type 2 diabetes mellitus. Dia-
betologia 2007;50:1509-1516. 
201. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Bies-
sels GJ. Brain imaging in patients with diabetes: a systematic 
review. Diabetes Care 2006;29:2539-2548. 
202. Torres ER, Strack EF, Fernandez CE, Tumey TA, Hitchcock ME. 
Physical activity and white matter hyperintensities: a system-
atic review of quantitative studies. Prev Med Rep 2015;2:319-
325.
203. Rha JH, Park HK, Park JJ, Yoo NY. Is antiplatelet treatment 
effective on the progression of white matter hyperintensity?: 
5 year follow up, propensity score adjusted, observational 
study. Neurology 2012;78(1 Suppl):P04.203. 
204. Yoon CW, Choi Y, Jeon S, Lee DH, Yoon BN, Park HK, et al. Is 
antiplatelet treatment effective at attenuating the progres-
sion of white matter hyperintensities? PLoS One 2017;12: 
e0176300. 
205. Qiu J, Ye H, Wang J, Yan J, Wang J, Wang Y. Antiplatelet 
therapy, cerebral microbleeds, and intracerebral hemorrhage: 
a meta-analysis. Stroke 2018;49:1751-1754.
206. Wobith M, Mayer C, Belke M, Haag A, Gerstner A, Teepker M, 
et al. Predictors of new cerebral microbleeds in patients with 
antiplatelet drug therapy. J Stroke Cerebrovasc Dis 2016; 
25:1671-1677.
207. Charidimou A, Shoamanesh A, Al-Shahi Salman R, Cordonni-
er C, Perry LA, Sheth KN, et al. Cerebral amyloid angiopathy, 
cerebral microbleeds and implications for anticoagulation 
decisions: the need for a balanced approach. Int J Stroke 
2018;13:117-120.
